Catherina X. Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Catherina X. Pan has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Vinod E. Nambudiri
Harvard Medical School, Boston, USA
10 shared publications Kevin Yang
Department of Dermatology Brigham and Women’s Hospital Boston MA 02115 USA
4 shared publicationsCharles B. Lau
Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115; Boston University, Boston, MA 02215
3 shared publicationsRachael Rowley
Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115
3 shared publicationsRuhi Kanwar
Harvard Medical School, Boston, MA 02115; Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115
3 shared publicationsWilliam C. Lau
Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115; Boston University School of Medicine, Boston, MA 02118
3 shared publications
Latest Publications
- 30 November 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 90 (4) , 826-829
Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors
- 30 November 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 90 (4) , 826-829
Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors
- 24 July 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (5) , 637-640
Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: a retrospective cohort study
In a large, multi-institutional cohort of 672 patients with melanoma, we examined the comparative incidence and severity of immune-related adverse events among patients receiving first-line immune checkpoint inhibitors. Comparing PD-1 inhibitors, nivolumab was associated with significantly lower risk of high-grade toxicity onset compared with pembrolizumab on unadjusted logistic regression analysis. Compared with pembrolizumab, use of the CTLA-4 inhibitor ipilimumab was associated with a significant increase in risk of gastrointestinal, but not endocrine and cutaneous toxicities.
- 24 July 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (5) , 637-640
Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: a retrospective cohort study
In a large, multi-institutional cohort of 672 patients with melanoma, we examined the comparative incidence and severity of immune-related adverse events among patients receiving first-line immune checkpoint inhibitors. Comparing PD-1 inhibitors, nivolumab was associated with significantly lower risk of high-grade toxicity onset compared with pembrolizumab on unadjusted logistic regression analysis. Compared with pembrolizumab, use of the CTLA-4 inhibitor ipilimumab was associated with a significant increase in risk of gastrointestinal, but not endocrine and cutaneous toxicities.
- 12 June 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 89 (4) , e169-e170
Response to the article by Barry et al entitled “Nonmelanoma skin cancer in patients with hereditary hemochromatosis: a case-control study”
- 12 June 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 89 (4) , e169-e170
Response to the article by Barry et al entitled “Nonmelanoma skin cancer in patients with hereditary hemochromatosis: a case-control study”
- 29 March 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 89 (2) , 361-364
Recurrent reactive infectious mucocutaneous eruption: A retrospective cohort study
- 29 March 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 89 (2) , 361-364
Recurrent reactive infectious mucocutaneous eruption: A retrospective cohort study
- 1 September 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (3) , 443-445
Assessment of the representation of black, indigenous and people of colour in dermatology clinical practice guidelines
- 1 September 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (3) , 443-445
Assessment of the representation of black, indigenous and people of colour in dermatology clinical practice guidelines
- 12 August 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (4) , E261-E263
Clinicopathologic features of lichen nitidus: a multicenter cohort
- 12 August 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (4) , E261-E263
Clinicopathologic features of lichen nitidus: a multicenter cohort
- 21 July 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 88 (3) , 692-694
Nonmelanoma skin cancer in patients with hereditary hemochromatosis: A case-control study
- 21 July 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 88 (3) , 692-694
Nonmelanoma skin cancer in patients with hereditary hemochromatosis: A case-control study
- Open Access
- 20 July 2022
- Published by Elsevier in JAAD Case Reports
- Vol. 27, 99-102
A 72-year-old man with nonhealing facial erosions and bullae
- 20 July 2022
- Published by Elsevier in JAAD Case Reports
- Vol. 27, 99-102
Open AccessA 72-year-old man with nonhealing facial erosions and bullae
- 12 May 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (6) , E364-E367
Barriers to practice in the United States: a national survey of international medical graduate dermatologists
- 12 May 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (6) , E364-E367
Barriers to practice in the United States: a national survey of international medical graduate dermatologists